Bevacizumab is a recombinant humanized anti-VEGF immunoglobulin, which was initially used in the treatment of metastatic cancers, but which is now widely used in ophthalmology for proliferative diabetic retinopathy, exudative macular degeneration, macular edema, retinal vein occlusions, and neovascular glaucoma [88]. Here, VEGFA is linked to metastatic malignant neoplasm.